Compare Arm Holdings plc (ARM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arm Holdings plc vs GeneDx Holdings Corp — how do they compare? Arm Holdings plc trades at $268.82 (market cap $287.22B), while GeneDx Holdings Corp trades at $81.63 (market cap $2.44B). The key difference: Arm Holdings plc is far larger — about 117.7× GeneDx Holdings Corp's market cap, and Arm Holdings plc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| ARM | WGS | |
|---|---|---|
Market Cap | $287.22B | $2.44B |
Sector | Technology | Technology |
52-Week High | $439.46 | $167.51 |
52-Week Low | $104.55 | $34.51 |
Enterprise Value | $283.79B | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $272.10, up 1.59% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported robust revenue growth, with fiscal 2025 revenue of $4.01 billion and net income of $792 million, and strong profitability margins. Analyst consensus is bullish with a 70.37% buy rating and a $329.80 price target, though valuation multiples remain elevated.
The outlook is positive given ARM's leadership in AI chip architecture and projected revenue growth to $5.2 billion in 2026. Key risks include high valuation multiples, smartphone market headwinds, and execution challenges in custom chip development. Upside potential exists if AI-driven demand continues, but investors should weigh growth prospects against premium pricing.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
